To the full analysis
Buyback calculator for Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical stock: key metrics
RAREUltragenyx Pharmaceutical had an operating margin of −79.5% and a return on invested capital (ROIC) of −35.4% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2011 | no data | no data | no data |
| 2012 | no data | no data | no data |
| 2013 | no data | no data | no data |
| 2014 | no data | no data | no data |
| 2015 | no data | no data | no data |
| 2016 | −137,647.4% | −186,471.4% | −184,867.7% |
| 2017 | 100.0% | −12,593.5% | −11,567.3% |
| 2018 | 97.8% | −721.2% | −383.7% |
| 2019 | 91.3% | −409.0% | −388.3% |
| 2020 | 97.7% | −121.8% | −68.8% |
| 2021 | 95.4% | −108.6% | −129.2% |
| 2022 | 92.2% | −178.6% | −194.7% |
| 2023 | 89.6% | −131.1% | −139.7% |
| 2024 | 86.3% | −95.7% | −101.6% |
| 2025 | 83.8% | −79.5% | −85.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2011 | −64.4% | −46.6% | −56.5% |
| 2012 | −19.4% | −26.2% | −18.5% |
| 2013 | −70.0% | −36.7% | −58.8% |
| 2014 | −32.3% | −37.5% | −30.2% |
| 2015 | −27.4% | −32.6% | −26.0% |
| 2016 | −51.9% | −38.7% | −45.5% |
| 2017 | −78.8% | −57.7% | −61.6% |
| 2018 | −32.5% | −55.1% | −27.5% |
| 2019 | −61.6% | −40.0% | −35.5% |
| 2020 | −16.2% | −20.0% | −10.6% |
| 2021 | −49.2% | −20.7% | −29.8% |
| 2022 | −100.0% | −39.1% | −45.8% |
| 2023 | −100.0% | −36.0% | −40.7% |
| 2024 | −100.0% | −35.7% | −37.9% |
| 2025 | 200.0% | −35.4% | −37.5% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2015)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.